US2018289836A1PendingUtilityA1

Complexes and methods of reducing inflammation

Assignee: SPILLER KARA LORRAINEPriority: Apr 5, 2017Filed: Apr 5, 2018Published: Oct 11, 2018
Est. expiryApr 5, 2037(~10.7 yrs left)· nominal 20-yr term from priority
A61K 47/6929A61P 29/00A61K 47/6923A61K 31/573A61K 47/52
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides compositions comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. In another aspect the invention comprises a method for reducing inflammation in a patient comprising locally administering a composition comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. In a further aspect, the invention comprises a method for reducing inflammation in a patient comprising locally administering a composition comprising octadecylamine surface-functionalized nanodiamonds, wherein no therapeutic agent is bound to the nanodiamonds.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A complex comprising octadecylamine surface-functionalized nanodiamonds and dexamethasone, wherein dexamethasone is bound to the octadecylamine surface-functionalized nanodiamonds. 
     
     
         2 . The complex of  claim 1 , wherein the dexamethasone forms a monolayer on the octadecylamine surface-functionalized nanodiamonds. 
     
     
         3 . The complex according to  claim 1  wherein the complex has a particle size of less than about 7 μm. 
     
     
         4 . The complex according to  claim 1  wherein the complex has a particle size of about 1-2 μm and/or a particle size of about 150 nm. 
     
     
         5 . A method of reducing inflammation in a patient, comprising administering the complex of  claim 1 . 
     
     
         6 . The method of  claim 5  wherein the site of inflammation is a lesion or diabetic ulcer. 
     
     
         7 . The method of  claim 5 , wherein the inflammation is caused by rheumatoid arthritis, Crohn's disease, asthma, inflammatory bowel disease, venous leg ulcers, diabetes, psoriasis or multiple sclerosis. 
     
     
         8 . The method according to  claim 5 , wherein the complex is delivered to the skin, the intestine, the lungs, trachea, or kidney of the subject. 
     
     
         9 . The method according to  claim 5 , wherein the patient's macrophages phagocytose the octadecylamine surface-functionalized nanodiamonds. 
     
     
         10 . The method according to  claim 5 , wherein the complex is locally administered. 
     
     
         11 . A method of reducing inflammation in a patient, comprising administering a composition comprising octadecylene surface-functionalized nanodiamonds, wherein the surface functionalized nanodiamonds do not bind a substantial amount of a therapeutic agent. 
     
     
         12 . The method of  claim 11  wherein the site of inflammation is a lesion or diabetic ulcer. 
     
     
         13 . The method of  claim 11 , wherein the inflammation is caused by rheumatoid arthritis, Crohn's disease, asthma, inflammatory bowel disease, venous leg ulcers, diabetes, psoriasis or multiple sclerosis. 
     
     
         14 . The method according to  claim 11 , wherein the composition is delivered to the skin, the intestine, the lungs, trachea, or kidney of the subject. 
     
     
         15 . The method according to  claim 11 , wherein the patient's macrophages phagocytose the surface-functionalized nanodiamonds. 
     
     
         16 . The method according to  claim 11 , wherein the surface-functionalized nanodiamonds have a particle size of less than about 7 μm. 
     
     
         17 . The method according to  claim 11 , wherein the surface-functionalized nanodiamonds have a particle size of about 1 μm. 
     
     
         18 . The method according to  claim 11 , wherein the surface-functionalized nanodiamonds are locally administered. 
     
     
         19 . A method of reducing a level of M2A macrophages in a patient comprising administering a composition comprising octadecylene surface-functionalized nanodiamonds, wherein the surface functionalized nanodiamonds do not bind a substantial amount of a therapeutic agent. 
     
     
         20 . The complex according to  claim 1 , wherein the nanodiamonds are aggregated, unaggregated or partially aggregated.

Join the waitlist — get patent alerts

Track US2018289836A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.